Healx vs Owkin

Owkin has a disclosed valuation of $1B, while Healx's valuation is not publicly available, making a direct size comparison difficult. Owkin employs 450 people.

Owkin has raised more in total funding at $334M, compared to Healx's $47M — a gap of $287M. Combined, the two companies have completed 3 known funding rounds.

Owkin holds the higher Awaira Score at 69/100, compared to Healx's 55/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 14-point gap that reflects meaningful differences in scale or traction.

Healx was founded by Tim Guilliams in 2014. Owkin was founded by Thomas Clozel in 2016. Visit each company's profile on Awaira for a full founder biography.

Healx: Healx uses AI to identify and develop treatments for rare diseases, applying graph neural networks and multi-omics data analysis to repurpose existing approved drugs for new orphan disease indications. The Cambridge-based company focuses exclusively on rare diseases, where the small patient populations and limited existing literature make traditional drug discovery economically unviable without computational approaches that can extract signal from sparse data.\n\nThe company raised a $47 million Series B led by Balderton Capital and includes strategic investors from the rare disease patient advocacy community. Healx has assembled a pipeline of repurposing candidates for conditions including Fragile X syndrome, tuberous sclerosis complex, and other rare neurodevelopmental disorders, with several candidates advancing into clinical studies. The company partners with patient advocacy groups to access natural history data and patient registries that inform its disease models.\n\nHealx operates in a rare disease AI market that is less crowded than oncology-focused drug discovery AI but equally challenging due to regulatory complexity and small trial populations. The company competes with Healios, BenevolentAI, and specialist rare disease biotechs that are increasingly adopting computational methods. Its exclusive focus on rare diseases and its community partnerships represent a defensible niche that larger generalist AI drug discovery platforms have not prioritised. Owkin: Owkin is a French AI healthcare company founded in 2016 that develops federated learning and privacy-preserving machine learning technologies for drug discovery and clinical research. The company operates a distributed AI platform enabling pharmaceutical companies, biotech firms, and research institutions to collaborate on data analysis without sharing sensitive patient information or proprietary datasets. Owkin's core technology utilizes federated learning, allowing multiple parties to train machine learning models collectively while maintaining data privacy and regulatory compliance, particularly under GDPR and HIPAA frameworks. The company has raised $334 million in total funding and achieved a $1.0 billion valuation, positioning it as a significant player in the intersection of AI, privacy-tech, and healthcare. Owkin operates in the Series B stage and serves pharmaceutical companies seeking to accelerate drug development through collaborative AI while preserving data confidentiality. The platform addresses a critical challenge in healthcare AI: enabling large-scale machine learning without centralizing sensitive medical data. Owkin's approach contrasts with traditional cloud-based analytics solutions by maintaining data sovereignty at source institutions. The company has established partnerships across the pharmaceutical and research sectors, though specific customer names and financial metrics remain Not disclosed. Its growth trajectory reflects expanding demand for privacy-preserving AI solutions in highly regulated healthcare markets. Owkin combines federated learning with healthcare applications, enabling collaborative AI research without compromising data privacy or regulatory compliance across distributed pharmaceutical ecosystems.

Healx was founded first in 2014, giving it 2 years of additional market experience. Owkin was founded later in 2016. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Healx has approximately 1-50 employees, while Owkin has approximately 450. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Healx and Owkin are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.